Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1997 1
1998 3
1999 5
2000 3
2001 1
2002 5
2003 2
2004 3
2005 8
2006 10
2007 9
2008 12
2009 12
2010 23
2011 9
2012 10
2013 15
2014 12
2015 5
2016 13
2017 8
2018 6
2019 4
2020 3
2021 9
2022 8
2023 1
2024 14
2025 7
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial.
Kallimath A, Deshpande S, Singh P, Garegrat R, Lakshminrusimha S, Maheshwari R, Suryawanshi P. Kallimath A, et al. BMC Pediatr. 2024 Nov 1;24(1):698. doi: 10.1186/s12887-024-05107-0. BMC Pediatr. 2024. PMID: 39487423 Free PMC article. Clinical Trial.
We aimed to compare oral sildenafil and bosentan as monotherapy in the treatment of neonates with PPHN. STUDY DESIGN: In this single-centre open-label randomized controlled trial (RCT), term and late preterm neonates with PPHN, defined as pulmonary arterial systolic pressu …
We aimed to compare oral sildenafil and bosentan as monotherapy in the treatment of neonates with PPHN. STUDY DESIGN: In this single- …
Bosentan and ambrisentan in the treatment of idiopathic pulmonary fibrosis: a meta-analysis.
Li HF, Wang JX, Xie ZF, Li LH, Li B, Huang FF, Li J, Zhou XL. Li HF, et al. Eur Rev Med Pharmacol Sci. 2024 Feb;28(3):1183-1193. doi: 10.26355/eurrev_202402_35357. Eur Rev Med Pharmacol Sci. 2024. PMID: 38375723 Free article.
OBJECTIVE: The aim is to showcase the effectiveness and safety of bosentan or ambrisentan in individuals diagnosed with idiopathic pulmonary fibrosis (IPF) and offer fresh evidence for the management of this condition. ...The rates of hospitalization and IPF worsening were …
OBJECTIVE: The aim is to showcase the effectiveness and safety of bosentan or ambrisentan in individuals diagnosed with idiopathic pu …
Bosentan in the treatment of persistent pulmonary hypertension in newborns: a systematic review and meta-analysis.
Gao N, Lv Y, Cui Y, Wang P, He X. Gao N, et al. Cardiol Young. 2024 Jun;34(6):1334-1341. doi: 10.1017/S1047951123004456. Epub 2024 Feb 8. Cardiol Young. 2024. PMID: 38329072
OBJECTIVES: To systematically evaluate the efficacy and safety of bosentan as an adjuvant therapy for persistent pulmonary hypertension of the newborn in newborns. ...The occurrence of adverse reactions was not significantly different between bosentan and a placebo …
OBJECTIVES: To systematically evaluate the efficacy and safety of bosentan as an adjuvant therapy for persistent pulmonary hypertensi …
Bosentan effect on echocardiographic systolic pulmonary arterial pressure in systemic sclerosis-related pulmonary hypertension: a systematic review and metanalysis.
Bearzi P, Navarini L, Currado D, Marino A, Minerba M, Salvolini C, Perrone A, Frascà L, Liakouli V, Vomero M, Berardicurti O, Giacomelli R. Bearzi P, et al. Clin Exp Rheumatol. 2024 Aug;42(8):1615-1622. doi: 10.55563/clinexprheumatol/xbdtb5. Epub 2024 May 28. Clin Exp Rheumatol. 2024. PMID: 38819960 Free article.
CONCLUSIONS: Bosentan significantly decreases sPAP, a relevant prognostic marker, especially in overt SSc-PAH. However, bosentan did not decrease sPAP when started for DU/mixed indication nor for follow-up>1 year. ...
CONCLUSIONS: Bosentan significantly decreases sPAP, a relevant prognostic marker, especially in overt SSc-PAH. However, bosentan …
Efficacy and safety of bosentan in the treatment of persistent pulmonary hypertension of the newborn: a Metaanalysis.
Li LX, Wei B, Yang M, Li M, Jia JJ. Li LX, et al. Zhongguo Dang Dai Er Ke Za Zhi. 2022 Mar 15;24(3):319-325. doi: 10.7499/j.issn.1008-8830.2109151. Zhongguo Dang Dai Er Ke Za Zhi. 2022. PMID: 35351265 Free PMC article. Chinese, English.
CONCLUSIONS: Bosentan is effective in the treatment of PPHN. However, when using bosentan, attention should be paid to adverse reactions such as abnormal liver function. ...CONCLUSIONS: Bosentan is effective in the treatment of PPHN. However, when using bo …
CONCLUSIONS: Bosentan is effective in the treatment of PPHN. However, when using bosentan, attention should be paid to adverse …
Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis.
Chen X, Zhai Z, Huang K, Xie W, Wan J, Wang C. Chen X, et al. Clin Respir J. 2018 Jun;12(6):2065-2074. doi: 10.1111/crj.12774. Epub 2018 Feb 22. Clin Respir J. 2018. PMID: 29393580
For both PAH and CTEPH, there was no significant difference in mortality or adverse event between bosentan and placebo group. However, bosentan raised the risk of abnormal liver function in both PAH and CTEPH patients. ...Incidence of liver function abnormality is h …
For both PAH and CTEPH, there was no significant difference in mortality or adverse event between bosentan and placebo group. However …
Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis.
Becattini C, Manina G, Busti C, Gennarini S, Agnelli G. Becattini C, et al. Thromb Res. 2010 Jul;126(1):e51-6. doi: 10.1016/j.thromres.2010.01.007. Epub 2010 Feb 21. Thromb Res. 2010. PMID: 20172593
We performed a systematic review and meta-analysis aimed at assessing the effects of bosentan therapy in patients with CTEPH. METHODS: We searched in MEDLINE and Embase using the terms 'pulmonary hypertension' AND 'bosentan'. ...Three patient died within 3-6 months …
We performed a systematic review and meta-analysis aimed at assessing the effects of bosentan therapy in patients with CTEPH. METHODS …
Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Galiè N, et al. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Circulation. 2009. PMID: 19470885 Clinical Trial.
METHODS AND RESULTS: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to …
METHODS AND RESULTS: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic …
Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q, Guo N, Chen J, Parks D, Tian Z. Zhao Q, et al. J Clin Pharm Ther. 2022 Feb;47(2):146-156. doi: 10.1111/jcpt.13481. Epub 2021 Jul 28. J Clin Pharm Ther. 2022. PMID: 34319626 Review.
RESULTS: Five clinical trials from four published studies (total patients: n = 920) were included. Ambrisentan and bosentan showed no significant difference in 6MWD (MD: -1.32; 95% CI: -27.87, 25.31, SUCRA score: ambrisentan 0.73, bosentan 0.77), BDI (MD: -0.16; 95% …
RESULTS: Five clinical trials from four published studies (total patients: n = 920) were included. Ambrisentan and bosentan showed no …
Bosentan and Pulmonary Hypertension Caused by COVID-19: A Pilot Randomized Double-blind Clinical Study.
Shokrollahi F, Pazoki A, Allami A, Aliakbari S, Ardali KR. Shokrollahi F, et al. Curr Vasc Pharmacol. 2024;22(6):437-446. doi: 10.2174/0115701611299843240607061547. Curr Vasc Pharmacol. 2024. PMID: 38874033 Clinical Trial.
An endothelin-1 (ET-1) receptor antagonist, such as bosentan, may be beneficial in treating elevated ET-1 levels. Hence, our study aimed to evaluate the therapeutic effects of bosentan in patients with COVID-19-induced PH. ...CONCLUSION: This study provided a mixed …
An endothelin-1 (ET-1) receptor antagonist, such as bosentan, may be beneficial in treating elevated ET-1 levels. Hence, our study ai …
190 results